Does Aetna Cover Wegovy? What the PA Actually Requires

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited

As of May 2026. Confirm directly with your plan. Coverage varies by employer plan, region, and time. Always confirm with your specific plan administrator.

Key Takeaways

• Aetna covers Wegovy for chronic weight management on plans that include weight-loss drug benefits, with PA
• The single largest variable is whether the employer plan includes weight-loss drug coverage at all. Many do not
• PA criteria track FDA labeling: BMI 30+, or BMI 27+ with a comorbidity. Some plans add documentation of structured lifestyle intervention
• Aetna Medicare Advantage covers Wegovy only for the cardiovascular indication after the November 2024 CMS rule
• Renewal criteria typically require 5% weight loss from baseline within 6 months

Direct answer

Aetna covers Wegovy for adults with obesity or overweight with a weight-related comorbidity when the prior authorization is approved and the employer plan includes weight-loss drug coverage. The PA requires BMI documentation, comorbidity diagnosis where applicable, age 18 or older, and lifestyle intervention history. As of May 2026, many Aetna employer plans exclude weight-loss drug coverage; in those plans, no clinical PA will produce coverage. Aetna Medicare Advantage covers Wegovy only for the cardiovascular indication.

Table of contents

1. Aetna's Wegovy coverage stance in 2026
2. The Aetna PA for Wegovy, walked through
3. BMI documentation: getting the numbers right
4. Comorbidity for BMI 27 to 29.9 patients
5. Lifestyle intervention: what documentation Aetna accepts
6. Step therapy: Saxenda before Wegovy on some plans
7. The employer plan layer: where coverage really gets decided
8. Aetna Medicare Advantage and the CV indication
9. Renewal criteria: the 5% weight-loss benchmark
10. Cost-sharing math with and without coverage
11. Building an Aetna appeal that gets reversed
12. External review path
13. If coverage fails: the FormBlends 503A alternative
14. Contrary view: Aetna's reasoning for tight PA
15. Decision framework
16. FAQ
17. Sources

Aetna's Wegovy coverage stance in 2026

Aetna's published clinical policy for GLP-1 receptor agonists in chronic weight management covers Wegovy for adults meeting FDA-labeled criteria, with prior authorization. The policy has tightened in some respects and loosened in others since Wegovy's June 2021 FDA approval.

The current Aetna stance:

• Wegovy is covered for the obesity and overweight-with-comorbidity indications on commercial plans that include weight-loss drug benefits
• Coverage requires PA documenting BMI, comorbidity (when applicable), and lifestyle intervention
• Initial approval is typically for 6 months
• Renewal requires documented weight loss of at least 5% from baseline
• Aetna Medicare Advantage covers Wegovy only for the cardiovascular indication (SELECT trial, FDA approval March 2024) under the November 2024 CMS rule

The Aetna PA for Wegovy, walked through

Aetna's PA form, administered through the Aetna Specialty pharmacy or CVS Caremark depending on the plan, asks for:

• Patient demographics and the prescriber information
• Diagnosis with ICD-10 code (E66.x for obesity, E66.9 for unspecified obesity, or the specific comorbidity code)
• Current BMI with measurement date, height, and weight
• Age 18 or older (or pediatric criteria for ages 12 to 17)
• Comorbidity diagnoses if BMI 27 to 29.9
• Prior weight-loss attempts including programs, dates, and outcomes
• Concurrent lifestyle intervention plan
• Confirmation that the prescription is within FDA labeling

The form is submitted via the Aetna provider portal or by fax. Decisions arrive within 72 hours for standard requests, 24 hours for expedited.

BMI documentation: getting the numbers right

BMI is the gatekeeper. Aetna's PA requires the BMI to be documented at a recent visit, not relied upon from a stale chart note. The reviewer wants to see:

• The measurement date
• The actual height and weight values
• The calculated BMI
• Confirmation that the measurement was clinical (not self-reported)

BMI of 30 or higher qualifies for the obesity indication. BMI of 27 to 29.9 qualifies for the overweight indication if a weight-related comorbidity is also documented.

Comorbidity for BMI 27 to 29.9 patients

Patients in the 27 to 29.9 BMI range need a documented comorbidity. Aetna accepts:

• Type 2 diabetes
• Hypertension
• Dyslipidemia
• Obstructive sleep apnea
• Cardiovascular disease
• Non-alcoholic fatty liver disease (on some plans)

The comorbidity must be documented and active. A historical hypertension diagnosis without current treatment or current BP elevation may not qualify. The PA reviewer often wants to see lab values, current medications, or specialist notes that confirm the comorbidity is real and ongoing.

Lifestyle intervention: what documentation Aetna accepts

Aetna's PA requires lifestyle intervention documentation. Acceptable evidence:

• Records of structured commercial weight-loss programs (WeightWatchers, Noom, etc.) with enrollment dates
• Dietitian or nutritionist visit records
• Chart notes from primary care visits where weight management was discussed in detail
• Records of exercise programs or memberships
• Behavioral health visits addressing eating patterns

Some plans require a documented prior attempt of 3 to 6 months. Others accept concurrent engagement. The PA criteria for your specific plan specify.

Step therapy: Saxenda before Wegovy on some plans

Aetna applies step therapy on some Wegovy PAs, particularly requiring Saxenda (liraglutide) before Wegovy. The clinical rationale is that Saxenda is in the same drug class and is less expensive per fill.

Step-therapy exceptions are available with documented clinical reasoning: prior Saxenda trial with inadequate response, intolerance, contraindication, or specific clinical reason. The prescriber documents the exception ground in the PA submission.

Step therapy with Wegovy is less common than with diabetes drugs. Most Aetna plans approve Wegovy directly when BMI and comorbidity criteria are met.

The employer plan layer: where coverage really gets decided

Aetna administers many self-funded employer plans. Under ERISA, the employer sets the benefit design. The employer can:

• Include weight-loss drug coverage with Aetna's standard PA (the most common configuration)
• Include weight-loss drug coverage with stricter PA than Aetna standard
• Exclude weight-loss drugs entirely
• Cover Wegovy only for the cardiovascular indication
• Require participation in a specific employer-sponsored weight-management program

Read your Summary of Benefits and Coverage and Evidence of Coverage. These documents control what your plan covers. The Aetna Clinical Policy Bulletin is the starting point, not the final word.

Aetna Medicare Advantage and the CV indication

Aetna Medicare Advantage plans cover Wegovy only for the cardiovascular indication, following the November 2024 CMS final rule. The criteria:

• Documented established cardiovascular disease (prior MI, stroke, peripheral artery disease, coronary revascularization)
• BMI 27 or higher
• Prescription written for the cardiovascular indication
• Standard Part D PA met

The Part D $2,000 annual out-of-pocket cap applies. The Novo Nordisk Wegovy Savings Card is not available to Medicare beneficiaries.

Renewal criteria: the 5% weight-loss benchmark

Aetna's Wegovy renewal criteria typically require 5% weight loss from baseline within 6 months. The renewal PA documents:

• Baseline weight at start of therapy
• Current weight at the renewal visit
• Percentage weight loss
• Continued engagement in lifestyle intervention
• Continued tolerability and lack of significant adverse effects

Patients who do not meet the 5% threshold at 6 months may not be approved for continued therapy. The clinical rationale is that non-response by 6 months is unlikely to convert to response with continued therapy at the same dose.

For patients on slow titration who have not reached the 2.4 mg maintenance dose at 6 months, renewal review may give weight to the dose trajectory. The PA reviewer takes the full clinical picture into account.

Cost-sharing math with and without coverage

Scenario	Approximate monthly cost
Aetna commercial, Wegovy covered, with manufacturer card	$0 to $25 (eligibility-dependent, annual cap)
Aetna commercial, Wegovy covered, no card	$25 to $200 copay
Aetna commercial, Wegovy not covered, with card	$650 for cash-pay eligible patients (terms vary)
Aetna commercial, Wegovy not covered, no card	$1,300 to $1,450 cash
Aetna Medicare Advantage, CV indication	$50 to $150, up to $2,000 OOP cap
Aetna Medicare Advantage, weight loss only	Not covered

Building an Aetna appeal that gets reversed

Aetna appeals reviewed by clinical pharmacists or medical directors. The strongest appeals address the specific denial reason with specific evidence.

For a BMI denial, recheck the documented BMI. If the value was wrong or stale, submit a corrected record. If the BMI is below 30 and below 27, the patient does not meet labeling and no appeal will succeed.

For a comorbidity denial (BMI 27 to 29.9), confirm the comorbidity is documented and active. Lab values, BP readings, sleep study reports, or specialist notes strengthen the file.

For a lifestyle intervention denial, submit the documentation that was missing: program enrollment records, dietitian notes, or detailed chart notes from primary care visits.

For a plan exclusion denial, internal appeal will not overturn the exclusion. The benefit design is the employer's choice.

External review path

If Aetna upholds the denial on internal appeal, external review under ACA Section 2719 applies for most commercial plans. The independent reviewer is a physician with relevant specialty. The decision is binding on Aetna.

External review will not overturn an employer plan exclusion of weight-loss drugs. The reviewer reviews medical necessity, not benefit design choices.

If coverage fails: the FormBlends 503A alternative

If Aetna will not cover Wegovy and the manufacturer card or patient assistance program cannot bridge the cost, 503A compounded semaglutide via telehealth is a path worth understanding.

503A compounded semaglutide is the same active molecule as Wegovy. It is not FDA-approved, is not equivalent to brand-name Wegovy, and is prepared individually by a state-licensed 503A pharmacy. The regulatory and supply pathways are different.

FormBlends works with state-licensed 503A pharmacies and licensed clinicians for clinically eligible patients. The model includes a telehealth visit, clinical evaluation, individualized prescribing if appropriate, and direct shipment. Compounded medication is cash-pay.

The choice between brand-name Wegovy with the savings card and 503A compounded is not just a price decision. The two products are not interchangeable. The choice should be made with a prescriber who knows the patient's history.

Contrary view: Aetna's reasoning for tight PA

Aetna's PA criteria look strict to a patient who would benefit from Wegovy. The actuarial defense:

Wegovy at retail is among the most expensive chronic medications in the formulary. If every Aetna commercial member who could clinically benefit from Wegovy filled it monthly, the plan-level cost would be substantial. That cost is passed back to all members through premiums.

The PA criteria, including the 5% renewal threshold, ensure that members starting Wegovy match the trial population and continue therapy only when they respond. Non-responders use plan dollars without benefit. The 5% threshold is consistent with FDA labeling guidance for continuation of obesity pharmacotherapy.

The counterargument is that real-world adherence is lower than trial conditions and that the 5% threshold may screen out patients who would respond with more time. The Endocrine Society and the Obesity Society have weighed in on continuation criteria with somewhat different framings. Reasonable people disagree.

Decision framework

If you have BMI 30+ or BMI 27+ with comorbidity and your Aetna plan covers weight-loss drugs: file the PA. Build the file correctly: BMI documented, comorbidity diagnosis with evidence, lifestyle intervention history.

If your Aetna employer plan excludes weight-loss drugs: the PA will not succeed. Pursue the manufacturer card, patient assistance, or 503A compounded.

If you are on Aetna Medicare Advantage with established cardiovascular disease: Wegovy may be coverable under the November 2024 CMS rule.

If you are at 6 months of Wegovy therapy and approaching renewal: document the weight loss and the continued lifestyle engagement. The 5% threshold matters.

FAQ

Does Aetna cover Wegovy? On plans that include weight-loss drug coverage, yes with PA. On plans without weight-loss drug coverage, no.

What's the BMI threshold? 30+, or 27+ with comorbidity.

What counts as comorbidity? T2D, hypertension, dyslipidemia, OSA, CVD, NAFLD on some plans.

How long is initial approval? Typically 6 months.

What's the renewal criterion? 5% weight loss from baseline.

Does Medicare Advantage cover it? Only for the cardiovascular indication.

How do I appeal? File within the deadline. Address the specific denial reason.

What if my employer excluded coverage? Internal appeal will not help. Card, assistance, or 503A.

Sources

1. Aetna Clinical Policy Bulletin: GLP-1 Receptor Agonists for Chronic Weight Management. 2026.
2. U.S. Food and Drug Administration. Wegovy prescribing information including SELECT cardiovascular indication.
3. Lincoff AM, et al. SELECT cardiovascular outcomes. NEJM. 2023;389:2221-2232.
4. Wilding JPH, et al. STEP 1. NEJM. 2021;384:989-1002.
5. Rubino D, et al. STEP 4. JAMA. 2021;325:1414-1425.
6. Centers for Medicare and Medicaid Services. Final rule on Part D coverage of GLP-1 for cardiovascular indications. November 2024.
7. Social Security Act, Section 1860D-2(e)(2). Part D weight-loss exclusion.
8. Affordable Care Act, Section 2719 external review.
9. Endocrine Society. Obesity pharmacotherapy clinical practice guideline.
10. Obesity Society. Position statements on obesity pharmacotherapy continuation.
11. Novo Nordisk. Wegovy Savings Card program terms.
12. U.S. Food and Drug Administration. 503A compounding regulations.

Footer disclaimers

Platform Disclaimer. FormBlends provides telehealth services through licensed clinicians. We do not administer Aetna plans or adjudicate Aetna claims. Information about Aetna policies reflects publicly available materials as of May 2026 and is subject to change.

Compounded Medication Notice. Compounded semaglutide is prepared by a state-licensed 503A pharmacy for an individual patient. It is not FDA-approved and is not equivalent to brand-name Wegovy. Clinical equivalence should not be assumed. The decision belongs with a prescribing clinician.

Results Disclaimer. Coverage and weight-loss outcomes vary. Examples and criteria here do not predict any specific case.

Trademark Notice. Wegovy, Saxenda, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Aetna is a registered trademark of Aetna Inc. CVS Caremark is a registered trademark of CVS Health. FormBlends is independent.